CRVS vs. SPRO, CNTB, TPST, ALRN, MRNS, ANEB, BYSI, DERM, LFVN, and VACC
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Tempest Therapeutics (TPST), Aileron Therapeutics (ALRN), Marinus Pharmaceuticals (MRNS), Anebulo Pharmaceuticals (ANEB), BeyondSpring (BYSI), Journey Medical (DERM), LifeVantage (LFVN), and Vaccitech (VACC). These companies are all part of the "pharmaceutical preparations" industry.
Corvus Pharmaceuticals (NASDAQ:CRVS) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 4.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Corvus Pharmaceuticals received 86 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.20% of users gave Spero Therapeutics an outperform vote while only 62.31% of users gave Corvus Pharmaceuticals an outperform vote.
In the previous week, Corvus Pharmaceuticals had 16 more articles in the media than Spero Therapeutics. MarketBeat recorded 18 mentions for Corvus Pharmaceuticals and 2 mentions for Spero Therapeutics. Corvus Pharmaceuticals' average media sentiment score of 0.61 beat Spero Therapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.
Corvus Pharmaceuticals presently has a consensus price target of $6.88, indicating a potential upside of 309.23%. Spero Therapeutics has a consensus price target of $7.00, indicating a potential upside of 321.69%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Corvus Pharmaceuticals.
Spero Therapeutics has a net margin of 21.98% compared to Corvus Pharmaceuticals' net margin of 0.00%. Spero Therapeutics' return on equity of 38.54% beat Corvus Pharmaceuticals' return on equity.
Spero Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corvus Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Summary
Spero Therapeutics beats Corvus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Corvus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
Related Companies and Tools
